CXRXF
Advanz Pharma
ADVANZ PHARMA Corp. is a multi-national pharmaceutical company headquartered in London. It changed its name from Concordia Healthcare Corp. in November 2018. The company focuses on a number of therapy areas including endocrinology, ophthalmology, urology, anti-infectives, pain management, central nervous system disorders, oncology, haematology, cardiology and intensive care medicine. The company also focuses on acquiring legacy pharmaceutical compounds which are usually off patent. ADVANZ PHARMA is a global pharmaceutical company with its operational headquarters in London, UK, operations centre in Mumbai, India and regional hubs in Europe, Australia and the US.
Index: OTC Markets; Sector: Healthcare; Industry: Biotechnology & Drugs;
Marketcap: 227.48M; Volume: 106.00; AvgVol 3m: 14.59K; Beta: 0.10;
Cost estimate:
P/E: –; EPS: -3.66; EPS growth quarter/prev quarter: –;
EPS growth this year: –; EPS growth past 5 years: –;
EPS ttm: –;
P/S: –; P/B: –; P/Cashflow: –; P/FCF: –;
Sales: 503.46M; Sales growth quarter/prev quarter: –; Sales growth past 5 years: –;
Profitability:
Gross Margin: –; Profit Margin: –; Operating Margin: –;
ROA – return on assets: –; ROE – return on equity: –; LT Debt/Equity: –; Total Debt/Equity: –;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: –; Insider Transactions:–;
Institutional Ownership: –; Institutional Transactions: –;
Data update: 07.10.2020.